INO Inovio: Rentabilitas operasi

Tandha merek Inovio Pharma (INO)

Inovio Pharmaceuticals (INO) is penetrating the biodefense and immunotherapy segment by utilizing unique drug delivery devices. The operating margin reflects current dynamics, with the indicator standing at -25953.80. The company is developing a DNA medicine ecosystem to combat cancer and viruses. However, a reliance on secondary offerings and delays in commercialization render the asset highly speculative, with a risk of a liquidity gap.

INO - Tingkat bathi operasi Inovio ing rentang 04.07.2022 - 19.11.2026

Inovio Pharmaceuticals - rincian analitis lan metrik utama (INO)

- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi saham perusahaan:
Analisis dhasar perusahaan:INO, Inovio Pharmaceuticals Inc
Produk dadi Inovio Pharma

Operating margin reflects cost management efficiency by expressing the share of profit from core operations relative to total revenue. Tracking the operating margin allows for an assessment of a business's ability to generate cash flow before accounting for financial obligations and taxes. The metric is calculated as the ratio of operating profit to the company's net income. For Inovio Pharmaceuticals (INO), this metric is critical as the company shifts its focus toward gene therapy for rare diseases. The indicator's trend demonstrates management's financial resilience during the commercialization of multi-year scientific developments.